---
title: "Sarepta's Former COO David Howton Sold $31.2M — Now Selling SLDB Stock at $6/Share"
type: news
slug: sarepta-howton-31-million-career-insider-sales
canonical_url: https://13finsight.com/news/sarepta-howton-31-million-career-insider-sales
published_at: 2026-03-01T18:13:15.406Z
updated_at: 2026-03-01T18:13:26.191Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 298
locale: en
source: 13F Insight
---

# Sarepta's Former COO David Howton Sold $31.2M — Now Selling SLDB Stock at $6/Share

> David Howton, former COO of Sarepta Therapeutics, sold $31.2M in SRPT stock. Now at Solid Biosciences, his recent filings show SLDB sales at just $5.82-$6.44/share.

David T. Howton, former COO of Sarepta Therapeutics (SRPT), accumulated $31.2 million in career stock sales across 120 transactions. Now at Solid Biosciences (SLDB), his February 2026 filings show a starkly different scale: selling 45,240 shares of SLDB at just $5.82-$6.44/share for roughly $286K total. The Numbers MetricValue Career Sell Value$31.2M Career Buy Value$0 Total Transactions120 Last Transaction2026-02-02 Shares Remaining105,077 Recent Activity DateTypeSharesPriceEst. Value 2026-02-18Sell7,469$5.8233$43K 2026-02-13Exercise14,687N/A$0 2026-02-13Exercise14,687N/A$0 2026-02-02Sell37,771$6.4369$243K 2026-01-31Exercise42,275N/A$0 Howton's transition from Sarepta to Solid Biosciences is visible in his Form 4 timeline. January-February 2026 filings show systematic SLDB option exercises (42K-79K shares) followed by sales at single-digit prices. The contrast with his Sarepta tenure — where individual transactions could reach millions — highlights the difference between a $10B+ rare disease leader and a $250M gene therapy company. What It Means Howton's career insider profile tells a story of two acts: $31.2M in Sarepta sales at premium biotech prices, followed by small-dollar SLDB selling at depressed valuations. The 105,077 shares remaining across his filings suggest he maintains meaningful exposure, but at ~$6/share that represents only ~$630K — a fraction of what a single Sarepta sale generated. The Sarepta-to-Solid-Biosciences career path is common in biotech: executives move from established rare disease companies to earlier-stage gene therapy plays. For SRPT investors, Howton's departure and complete divestiture removes a long-tenured operator from the shareholder base. For SLDB watchers, a former Sarepta COO selling at $6 from a company developing DMD gene therapies adds an insider sentiment data point — though early-stage biotech selling is often driven by exercise deadlines rather than conviction. What to Watch Whether Howton continues exercising and selling SLDB options in Q1 2026 Solid Biosciences' DMD gene therapy clinical data readouts Sarepta's Elevidys commercial trajectory under new leadership Any additional career moves that generate new Form 4 filings

---

Source: 13F Insight — https://13finsight.com/news/sarepta-howton-31-million-career-insider-sales
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-01T18:13:26.191Z